# Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

> **NCT01710644** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nordmark Arzneimittel GmbH & Co. KG** · enrollment: 35 (actual)

## Conditions studied

- Pancreatic Insufficiency
- Cystic Fibrosis
- Digestive System Diseases
- Lung Diseases
- Respiratory Tract Diseases

## Interventions

- **DRUG:** Burlulipase
- **DRUG:** Placebo (Caramel in sterile water)

## Key facts

- **NCT ID:** NCT01710644
- **Lead sponsor:** Nordmark Arzneimittel GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-07
- **Final completion:** 2014-08
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2016-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01710644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01710644, "Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01710644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*